GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

From 2010 to 2023, there was an increase in prescribing of GLP-1 RAs and SGLT2 inhibitors among individuals with type 1 diabetes (T1D).

Greatest increase in SGLT2 inhibitor use seen in subgroups with cardiovascular disease; greatest increase in GLP-1 RA for those with obesity. (HealthDay News) — From 2010 to 2023, there was an ...

To explore this further, researchers set out to compare the effects of SGLT-2 inhibitors on risk of recurrent kidney stones and gout with two other groups of diabetes drugs known as GLP-1 receptor ...

Objective Sodium–glucose cotransporter 2 (SGLT-2) inhibitors are the most recently approved antihyperglycemic medications. We sought to describe their association with euglycemic diabetic ...

To explore this further, researchers set out to compare the effects of SGLT-2 inhibitors on risk of recurrent kidney stones and gout with two other groups of diabetes drugs known as GLP-1 receptor ...

"This prognostic imbalance implies, in particular, that any comparison of outcomes between the patients in the empagliflozin group who started an SGLT2 inhibitor post-trial and those in the ...

The use of SGLT2 inhibitors was associated with a significantly reduced risk for dementia and PD in patients with type 2 diabetes.

Use vs non-use of sodium-glucose cotransporter 2 inhibitors by older patients with CKD stages 4-5D is significantly associated with reductions in all-cause mortality risk at 6, 12, and 60 months.

With a vote of 11-3, the Endocrinologic and Metabolic Drugs Advisory Committee said the benefits of the dual SGLT1/SGLT2 inhibitor do not outweigh the risks in this patient population, with a ...

Greatest increase in SGLT2 inhibitor use seen in subgroups with cardiovascular disease; greatest increase in GLP-1 RA for those with obesity. HealthDay News — From 2010 to 2023, there was an ...